Literature DB >> 24844789

A case of neuromyotonia in Behçet disease during TNF-α antagonist therapy.

Marco Belluzzo1, Massimo Dozzo, Erika Pigatto, Franco Schiavon, Fabrizio Monti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24844789     DOI： 10.1007/s10072-014-1820-7

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  5 in total

1.  Peripheral nerve hyperexcitability: a clinical and immunologic study of 38 patients.

Authors:  I Rubio-Agusti; F Perez-Miralles; T Sevilla; N Muelas; M J Chumillas; F Mayordomo; I Azorin; E Carmona; F Moscardo; J Palau; L Jacobson; A Vincent; J J Vilchez; L Bataller
Journal:  Neurology       Date:  2011-01-11       Impact factor: 9.910

Review 2.  Neuromyotonia.

Authors:  Paul Maddison
Journal:  Clin Neurophysiol       Date:  2006-07-14       Impact factor: 3.708

3.  Phenotypic variants of autoimmune peripheral nerve hyperexcitability.

Authors:  Ian K Hart; Paul Maddison; John Newsom-Davis; Angela Vincent; Kerry R Mills
Journal:  Brain       Date:  2002-08       Impact factor: 13.501

Review 4.  Tumor necrosis factor-alpha antagonists and neuropathy.

Authors:  Joerg-Patrick Stübgen
Journal:  Muscle Nerve       Date:  2008-03       Impact factor: 3.217

Review 5.  Neuro-Behçet's disease: epidemiology, clinical characteristics, and management.

Authors:  Adnan Al-Araji; Desmond P Kidd
Journal:  Lancet Neurol       Date:  2009-02       Impact factor: 44.182
  5 in total
  1 in total

1.  Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease.

Authors:  Antonio Vitale; Giacomo Emmi; Giuseppe Lopalco; Claudia Fabiani; Stefano Gentileschi; Elena Silvestri; Di Scala Gerardo; Florenzo Iannone; Bruno Frediani; Mauro Galeazzi; Giovanni Lapadula; Donato Rigante; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2017-04-11       Impact factor: 2.980
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.